HOME >> BIOLOGY >> NEWS
JCI table of contents, 2 August, 2004

Stroking Up Cellular Therapy

Stroke is the second largest cause of death worldwide and the leading cause of long-term neurological disability. Therapies for stroke victims are improving, but remain hampered by the limited repair capacity of nerves in the brain and the unique properties of brain vasculature. Akihiko Taguchi and colleagues, of the National Cardiovascular Center in Japan, make great strides in providing new means to aid stroke victims with their current work showing that intravenous injection of specific immune cells called CD34+ cells after stroke greatly enhances nerve restoration in the region of damage in mice. The authors isolated CD34+ cells from human cord blood and injected them into mice within 48 hours of a stroke. These mice experienced increase new blood vessel growth in stoke-damaged region. The CD34+ cells also produced growth factors to aid in neural regeneration. There was also evidence of migration of nerve progenitors into the region of stroke damage. The mice that were treated with CD34+ cells showed improved behavioral characteristics. Of note, if blockers to blood vessel growth were given in addition to the CD34+ cells, all of the benefits of CD34+ treatment were lost. These data provide direct evidence that new blood vessel growth is essential for repairing stroke damage, and provide important information for investigating therapies for this deadly and debilitating affliction.

An accompanying commentary by Daniel Peterson, of the Rosalind Franklin University of Medicine and Science, places these data into the context of the difficulties of treating stroke victims, and what additional information beyond this study is required to best understand how these data will be useful for understanding and treating stroke patients.

TITLE: Administration of CD34+ cells after stroke enhances neurogenesis via angiogenesis in a mouse model

AUTHOR CONTACT:
Akihiko Taguchi National Cardiovasc
'"/>

Contact: Laurie Goodman
press_releases@the-jci.org
212-342-4159
Journal of Clinical Investigation
2-Aug-2004


Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology news :

1. Chemical engineering grad students will take notable national awards
2. New study indicates arsenic could be suitable as first-line treatment in type of leukaemia
3. JCI table of contents September 15, 2004
4. JCI table of contents: 1 September, 2004
5. Anti-cancer compound in vegetables found to block late-stage breast-cancer cell growth
6. JCI table of contents, 16 August, 2004
7. When male fish hum, females swim in, thanks to hormones, adaptable hearing
8. JCI table of contents, 1 July 2004
9. Search and destroy protein turns tables on HIV
10. JCI table of contents, 15 June 2004
11. JCI table of contents, 1 June 2004

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: JCI table contents August

(Date:5/21/2013)... Mo. Cancers of all types become most deadly ... Once cancer has reached this stage, it becomes very ... tumors that can develop. Now, researchers at the University ... nanoparticles that target lymphoma tumor cells wherever they may ... of oncology in the MU College of Veterinary Medicine, ...
(Date:5/21/2013)... Society (ACS), the world,s largest scientific society, invites ... & Exposition, September 8-12, 2013, in Indianapolis, Ind. ... Center and at area hotels. , With more ... science,s horizons from astronomy to zoology ― ... journalists a rich assortment of spot news and ...
(Date:5/21/2013)... epigenetic modifications, which alter the way genes function ... be detected in the blood of pregnant women ... to foretell depression in the weeks after giving ... become debilitating. , The findings of the small ... in the journal Molecular Psychiatry . , ...
Breaking Biology News(10 mins):MU researchers develop radioactive nanoparticles that target cancer cells 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3
(Date:5/22/2013)... CAMBRIDGE, Mass. , May 22, 2013  Moderna ... revolutionary new treatment modality to enable the in ... John Reynders will join Moderna ... Reynders is a proven leader in ... phases of drug development, from discovery to translation, clinical ...
(Date:5/21/2013)... 2013 Through science fairs, workshops, kits ... lab equipment, 25 organizations will continue their work to ... and photonics in daily life with the aid of ... located in 10 countries, are the first of two ... SPIE, the international society for optics and photonics ...
(Date:5/21/2013)... 2013 Clinverse, Inc. , ... clinical trials, announced today it has formed a ... Clinverse’s ClinPay® FLS eClinical commerce platform aggregates data ... SpendMD ™, Aggregate Spend Solutions’ recently-launched flagship ... and reporting transfer of value at investigator meetings ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Emerson ... announced that Dr. Charles Signorino, the Company’s Chief Executive ... 1, 2013 after 32 years of service. As part ... Emerson’s current President, has been named as Dr. Signorino’s ... in the pharmaceutical industry, having made a significant contribution ...
Breaking Biology Technology:Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 2Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 3Learning About Light: Education Outreach Projects Funded in 10 Countries Through First Round of SPIE Grants 2Learning About Light: Education Outreach Projects Funded in 10 Countries Through First Round of SPIE Grants 3Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3Emerson Resources Announces CEO Retirement and Appointment of Successor 2Emerson Resources Announces CEO Retirement and Appointment of Successor 3
Cached News: